Chronic HIV-1 infection frequently fails to protect against superinfectionNovember 16, 2007Natural HIV-1 infection does not always elicit a protective immune response, according to a new study published November 16 in PLoS Pathogens. The team of researchers from Washington University, the Fred Hutchinson Cancer Research Center of Seattle, and the University of Nairobi show how HIV-1 vaccines may not be as reliable against superinfection as once thought. Superinfection of HIV-1 occurs when an individual infected with one strain of HIV-1 acquires a second strain. Currently there are over 20 published cases of HIV-1 superinfection, most of which have been focused on individuals who have been carefully monitored during their infection. These cases prove that an HIV-1 vaccine may not always protect against infection by a different strain. But because there have been reports of selected individuals, it has been unclear how commonly HIV-1 re-infection occurs. To address this question, Dr. Julie Overbaugh and her research team investigated the incidence of HIV-1 superinfection in 36 high-risk women followed roughly five years after their initial infection. Seven cases of superinfection were found; five of them occurring over a year past initial infection. Additionally, three of the seven cases displayed a virus from the same HIV-1 genetic subtype. This study suggests that immune responses found in natural HIV-1 infection, which fail to provide protection against re-infection, may not be the best path to an effective HIV-1 vaccine. Public Library of Science |
|||||||||||||||||||||
| Related Hiv-1 Infection Current Events and Hiv-1 Infection News Articles Maternal HIV-1 treatment protects against transmission to newborns Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding. Genetic Variation Associated With Survival Advantage in African Americans With HIV From the start of the HIV epidemic, it appeared that some of the people who were infected with the virus were able to ward off the fatal effects of the disease longer than others. Study offers insights into failed HIV-1 vaccine trial Following the disbandment of the STEP trial to test the efficacy of the Merck HIV-1 vaccine candidate in 2007, the leading explanation for why the vaccine was ineffective - and may have even increased susceptibility to acquiring the virus - centered on the hypothesis that high levels of baseline Ad5-specific neutralizing antibodies may have increased HIV-1 acquisition among the study subjects who received the vaccine by increasing Ad5-specific CD4+ T-cells that were susceptible to HIV-1 infection. MicroRNAs help control HIV life cycle Scientists at Burnham Institute for Medical Research (Burnham) have discovered that specific microRNAs (non-coding RNAs that interfere with gene expression) reduce HIV replication and infectivity in human T-cells. HIV conquers immune system faster than previously realized New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood. Exhaustion of HIV-specific T cells may be caused by chronic exposure to virus The "exhaustion" of immune cells that target HIV appears to result from chronic exposure to the virus, specifically exposure to the particular protein segments targeted by the pathogen-killing HIV-specific CD8 T cells. U of M researchers determine structure of protein that mutates DNA of the AIDS virus HIV-1 Understanding the structure of proteins involved in inhibiting HIV-1 infection could help in the battle against AIDS, and University of Minnesota researchers have taken a crucial step in that direction. Uncovering the Achilles' heel of the HIV-1 envelope New structural details illustrate how a promising class of antibodies may block human immunodeficiency virus (HIV)-1 infection and reveal valuable clues for design of an effective HIV-1 vaccine. Socioeconomic Position Associated with Effectiveness of HIV Drugs, Even Among Subjects Adhering to Treatment Schedules Socioeconomic position is a determinant of antiretroviral treatment effectiveness during initial therapy for HIV-1 infection. Defense peptide found in primates may block some human HIV transmissions As primates evolved 7 million years ago, the more advanced species stopped making a protein that University of Central Florida researchers believe can effectively block the HIV-1 virus from entering and infecting blood cells. More Hiv-1 Infection Current Events and Hiv-1 Infection News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||